IBD or Inflammatory Bowel Disease ranks as one of the most common illnesses affecting a staggering portion of the global population. Research shows that over 10 million people worldwide suffer from IBD, and 3.1 million are from the US alone. Alarmed by this increasing number of patients, leading American medical centers scour for the latest healthcare treatments that are equally accessible and effective.
A host of pharmaceutical agents has recently become available for the treatment of IBD. However, a significant subset of patients still finds the current strategies inefficient to ease and control their symptoms. Moreover, adverse events, costs, and prolonged pre-authorization procedures may limit some patients' access to these treatments. Hence, there is a growing interest in using nutraceuticals to treat IBD, especially as patients continue to look for “natural remedies” and turn to their doctors for information on clinically proven, safe methods.
At Sheba Medical Center in Israel, Prof. Shomron Ben-Horin (Chief of Gastroenterology) and Nir Salomon (Director of Integrative Gastroenterology) have developed a nutraceutical formula dubbed CurQD which has been used since 2017 to treat IBD patients with unprecedented success. They have recently reported and published their clinical data, drawing significant attention from leading medical centers in the USA and elsewhere. Evinature, a Sheba spin-off company, was founded to disseminate this novel treatment outside of Israel.
What is the CurQD Protocol?
The CurQD Protocol combines natural and clinically validated treatment regimens, highly customized to target each patient’s IBD stage. Based on the most potent formulation as per the results of placebo-controlled trials, the CurQD Protocol has been proven highly effective, accessible, and convenient for patients.
The CurQD is a natural blend of herbal extracts that have been clinically tested to provide quick and lasting relief. The formula has undergone rigorous placebo-controlled trials to identify the optimal ratio for each stage of treatment. What’s more, it is designed to offer a comprehensive and efficient solution for all individuals, ensuring a safe and rapid recovery.
This holistic treatment was developed and tested by renowned gastrointestinal experts to address the varying severity levels of the disease. With individualized formulations, the CurQD Protocol offers a safe and natural solution that is tailored to meet the specific needs of each patient.
Taking the Protocol to the US
Nir, who is currently the Head of R&D and Co-Founder of Evinature, recently gave a series of lectures at some of the top medical centers in the US to shine a light on the importance of integrative therapies for IBD and how combining traditional and alternative medicine can improve healthcare for IBD patients. He also discussed how Evinature's tailored protocols, guided care, and evidence-based treatments are transforming the way IBD is treated.
“By integrating clinically proven nutraceuticals into standard medical care, patients with IBD can benefit from personalized treatments based on scientific evidence, which may improve their overall well-being,” Nir said. “It is with great privilege that I look forward to sharing our research data and experience with colleagues from leading IBD centers throughout the United States. Equally, I'm excited to learn from their viewpoints and opinions, which could broaden our perspective and help promote this unique clinical approach.”
Evinature is creating a network of prominent medical centers throughout the United States to conduct joint research on non-pharmaceutical treatments, including CurQD, for gastrointestinal diseases. The company’s goal is to give patients multifaceted options for natural remedies that are equally effective and affordable and can be incorporated into standard medical practice with guided care. Evinature takes pride in collaborating with esteemed medical professionals from around the country to enhance the well-being of those living with IBD.